Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/28/2018 |
| Start Date: | September 2015 |
| End Date: | December 2020 |
| Contact: | TG Therapeutics Clinical Support Team |
| Email: | clinicalsupport@tgtxinc.com |
| Phone: | 212-554-4484 |
Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT)
The purpose of this study is to evaluate the safety and effectiveness of pembrolizumab in
combination with ublituximab and TGR-1202, in patients with advanced CLL or Richter's
Transformation.
combination with ublituximab and TGR-1202, in patients with advanced CLL or Richter's
Transformation.
Inclusion Criteria:
- Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation
- Refractory to or relapsed after at least 1 prior treatment regimen
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria:
- Any major surgery, chemotherapy or immunotherapy within the last 14 days
- Known hepatitis B virus, hepatitis C virus or HIV infection
- Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials